VANCOUVER, March 11, 2013 /CNW/ - Abattis Bioceuticals Corp. ("Abattis"
or the "Company") (CNSX: FLU) (OTC: ATTBF), announces that it will not
be proceeding with its $600,000 non-brokered private placement as
previously announced in its Press Release dated February 12, 2013 as it
is canvassing other avenues of financing through strategic
relationships to prevent any dilution for its shareholders.
About Abattis Bioceuticals Corp.
Abattis Bioceuticals Corp. is a specialty biotechnology company with
capabilities through its wholly owned subsidiaries of producing,
licensing and marketing proprietary ingredients and products containing
standardized phytochemicals for sale in Pharmaceutical, Nutraceutical,
Cosmetic and Animal Nutrition markets. The company also has a deep
pipeline of proprietary products ready for sale in high growth areas of
Functional Foods and Supplements business. For more information, visit
the Company's website at www.abattis.com.
ON BEHALF OF THE BOARD
President & CEO
Neither the CNSX Exchange nor its regulations services accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: Abattis Bioceuticals Corp.
For further information: